×
About 2,928 results

ALLMedicine™ Hemochromatosis Center

Research & Reviews  929 results

Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1 (DMT1): Preclinical E...
https://doi.org/10.1124/jpet.122.001435
The Journal of Pharmacology and Experimental Therapeutics; Cutts AJ, Chowdhury S et. al.

Mar 24th, 2023 - Divalent metal transporter 1 (DMT1) cotransports ferrous iron and protons and is the primary mechanism for uptake of nonheme iron by enterocytes. Inhibitors are potentially useful as therapeutic agents to treat iron overload disorders such as here...

Iron homeostasis governs erythroid phenotype in Polycythemia Vera.
https://doi.org/10.1182/blood.2022016779
Blood Bennett C, Jackson VE et. al.

Mar 18th, 2023 - Polycythemia Vera (PV) is a myeloproliferative neoplasm driven by activating mutations in JAK2 that result in unrestrained erythrocyte production, increasing patients' hematocrit and hemoglobin concentration, placing them at risk of life-threateni...

Juvenile Hemochromatosis With Non-transfused Hemolytic Anemia Caused by a De Novo PIEZO...
https://doi.org/10.1097/MPH.0000000000002639
Journal of Pediatric Hematology/oncology; Imashuku S, Suemori SI et. al.

Mar 11th, 2023 - Differential diagnosis of juvenile hemochromatosis along with hemolytic anemia is often difficult. We report a 23-year-old woman with macrocytic hemolytic anemia with iron overload. The patient showed high serum ferritin and transferrin saturation...

Percutaneous Liver Biopsy
https://emedicine.medscape.com/article/149684-overview

Mar 10th, 2023 - Background Percutaneous liver biopsy is a procedure in which a long needle is introduced through the skin, subcutaneous tissues, intercostal muscles, and peritoneum into the liver to obtain a specimen of liver tissue. [1, 2] This procedure is usua...

Percutaneous Liver Biopsy
https://emedicine.medscape.com/article/149684-print

Mar 10th, 2023 - Background Percutaneous liver biopsy is a procedure in which a long needle is introduced through the skin, subcutaneous tissues, intercostal muscles, and peritoneum into the liver to obtain a specimen of liver tissue.[1, 2] This procedure is usual...

see more →

Guidelines  5 results

ACG Clinical Guideline: Hereditary Hemochromatosis.
https://doi.org/10.14309/ajg.0000000000000315
The American Journal of Gastroenterology; Kowdley KV, Brown KE et. al.

Jul 25th, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic tes...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929861
European Journal of Human Genetics : EJHG; Porto G, Brissot P et. al.

Jul 15th, 2015 - Molecular genetic testing for hereditary hemochromatosis (HH) is recognized as a reference test to confirm the diagnosis of suspected HH or to predict its risk. The vast majority (typically >90%) of patients with clinically characterized HH are ho...

Diagnosis and management of hemochromatosis: 2011 practice guideline by the American As...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125
Hepatology (Baltimore, Md.); Bacon BR, Adams PC et. al.

Apr 1st, 2011 - Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.|2011|Bacon BR,Adams PC,Kowdley KV,Powell LW,Tavill AS,|blood,diagnosis,physiopathology,therapy,metabolism,pathology,m...

EASL clinical practice guidelines for HFE hemochromatosis.
https://doi.org/10.1016/j.jhep.2010.03.001
Journal of Hepatology;

May 18th, 2010 - Iron overload in humans is associated with a variety of genetic and acquired conditions. Of these, HFE hemochromatosis (HFE-HC) is by far the most frequent and most well-defined inherited cause when considering epidemiological aspects and risks fo...

see more →

Drugs  41 results see all →

Clinicaltrials.gov  72 results

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03323346

Mar 8th, 2023 - Inclusion criteria: Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques Histologically or cytologically confirmed tumor Age of 18 years or more Eastern Cooperative Oncology Group (ECOG) performance s...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Mar 6th, 2023 - Study Description: This is a clinical research protocol to allow for collection of samples and data obtained during clinical evaluation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to cre...

Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
https://clinicaltrials.gov/ct2/show/NCT05742035

Feb 23rd, 2023 - Iron overload in hereditary hemochromatosis is treated by phlebotomy. In Switzerland and in many other coutries, these individuals are not accepted for blood donation until ferritin values and phlebotomy intervals are in the normal range. Individu...

Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
https://clinicaltrials.gov/ct2/show/NCT04770870

Feb 14th, 2023 - The Hintermann Series H3® (H3) prosthesis is a mobile bearing total ankle replacement (TAR) indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arth...

Cardiac Function in Patients With Hereditary Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT00068159

Feb 8th, 2023 - Hereditary hemochromatosis (HH) is the most common hereditary metabolic abnormality among Caucasians. Homozygosity for the Cys282Tyr mutation, which is the most common known mutation with a predisposition to iron overload, occurs with an estimated...

see more →

News  93 results

Iron Screening in Alopecia Areata Patients May Catch Hereditary Hemochromatosis Early
https://www.mdedge.com/dermatology/article/259165/hair-nails/iron-screening-alopecia-areata-patients-may-catch-hereditary
Bonnie Leung, BSc, Linsey Lindley, MD, PhD et. al.

Nov 2nd, 2022 - The role of micronutrients in the hair follicle cycle is not fully understood; thus deficiency and/or excess of certain micronutrients may be a modifiable risk factor associated with the development and/or treatment of some types of hair loss and.

High Iron Levels Predict Greater Fracture Risk, More So in Men
https://www.medscape.com/viewarticle/981152

Sep 21st, 2022 - Patients with iron overload — serum ferritin > 1000 µg/L or a diagnosis of hemochromatosis or thalassemia — were 60% more likely to have an osteoporotic fracture during an up to 10-year follow-up than matched control patients, in a large study. Co...

American Oncology Network Physicians Research is Well Represented at the ASH Annual Meeting & Exposition
https://www.onclive.com/view/american-oncology-network-physicians-research-is-well-represented-at-the-ash-annual-meeting-exposition

Dec 23rd, 2021 - American Oncology Network, LLC (AON) is pleased to announce that eight research studies co-authored by AON physicians were presented at the American Society of Hematology (ASH) Annual Meeting & Exposition, held December 11-14, 2021. Abstracts sub...

FDA Lifts Hold on Rusfertide Clinical Development Program
https://www.onclive.com/view/fda-lifts-hold-on-rusfertide-clinical-development-program

Oct 12th, 2021 - The FDA has removed the full clinical hold that had previously been placed on trials evaluating rusfertide (PTG-300), according to an announcement from Protagonist Therapeutics, Inc.1 With this decision, dosing on all studies evaluating the agent ...

Dr. Fitzgerald on Minimizing Use of Chemotherapy in Breast Cancer
https://www.onclive.com/view/dr-fitzgerald-on-minimizing-use-of-chemotherapy-in-breast-cancer

Oct 6th, 2021 - Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial, which found that for intermediate-risk women wit...

see more →

Patient Education  31 results see all →